Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?

Hepatology

Volumn 58, Issue 3, 2013, Pages 1166-1174

  Kwok, Ryan M ^a   Torres, Dawn M ^a   Harrison, Stephen A ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; 7 DEHYDROCHOLESTEROL; ADIPOCYTOKINE; ADIPONECTIN; CALCIUM; CATHELICIDIN; COLECALCIFEROL; DNA; ERGOCALCIFEROL; FARNESOID X RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR; RETINOID X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DNA DAMAGE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HERITABILITY; HORMONE SYNTHESIS; HUMAN; HYDROXYLATION; INCIDENCE; INFLAMMATION; INTESTINE FLORA; INTRAABDOMINAL FAT; KERATINOCYTE; LIPOGENESIS; LIVER FIBROSIS; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEDENTARY LIFESTYLE; SINGLE NUCLEOTIDE POLYMORPHISM; STELLATE CELL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN D RESPONSIVE ELEMENT; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FATTY LIVER; HOMEOSTASIS; HUMANS; OBESITY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84883259255     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26390     Document Type: Article

References (74)

1. Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2001;25:531-541.
2. Ponchon G, Kennan AL, DeLuca HF. Activation of vitamin D by the liver. J Clin Invest 1969;48:2032-2037.
3. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-568.
4. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Endocrinol Metab Clin North Am 2010;39:243-253.
5. Wjst M, Altmuller J, Braig C, Bahnweg M, Andre E. A genome-wide linkage scan for 25-OH-D(3) and 1, 25-(0H)2-D3 serum levels in asthma families. J Steroid Biochem Mol Biol 2007;103:799-802.
6. Arguelles LM, Langman CB, Ariza AJ, Ali FN, Dilley K, Price H, et al. Heritability and environmental factors affecting vitamin D status in rural Chinese adolescent twins. J Clin Endocrinol Metab 2009;94:3273-3281.
7. Bu FX, Armas L, Lappe J, Zhou Y, Gao G, Wang HW, et al. Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet 2010;128:549-556.
8. Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev 2007;23:631-636.
9. Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hep Gastro 2011;35:295-302.
10. Bikle B. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009;94:26-34.
11. Van Etten E, Matheiu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101.
12. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 2000;120:139-146.
13. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D mediated human antimicrobial response. Science 2006;311:1770-1773.
14. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1, 25 dihdroxyvitamin D3 on human B cell differentiation. J Immunol 2007;179:1634-1647.
15. Rigby WF, Stacy T, Fanger MW. Inhibition of T lymphocyte mitogenesis by 1, 25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 1984;74:1451-1455.
16. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1a, 25-dihydroxyvitamin D3 has a direct effect on naïve CD4(+)T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974-4980.
17. Lemire JM, Archer DC, Beck L, Speigelberg HL. Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995;125:1704S-1708S.
18. Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hupperts R, et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1, 25 dihydroxyvitamin D, parathyroid hormone, and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol 2010;121:243-246.
19. Von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010;11:344-349.
20. Campbell IT, Jarrett RJ, Rutland P, Stimmler L. The plasma insulin and growth hormone response to oral glucose: diurnal and seasonal observations in the Antarctic. Diabetologia 1975;11:147-150.
21. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nut 2011;65:1005-1015.
22. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003;17:509-511.
23. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 2004;89-90:121-125.
24. Maestro B, Davila N, Carranza MC, Calle C. Identification of vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84:223-230.
25. Maestro B, Molero S, Bajo S, Davila N, Calle C. Transcriptional activation of the human insulin receptor gene by 1, 25-dihydroxyvitamin D(3). Cell Biochem Funct 2002;20:227-232.
26. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Al_Othman A, Draz HM, et al. Hypovitamosis D associations with adverse metabolic parameters are accentuated in patients with diabetes mellitus type 2: a BMI-independent role of adiponectin. J Endocrinol Invest 2013;36:1-6.
27. Li YC, King J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-238.
28. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, et al. The adipose-tissue renin-angiotensin aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35:807-825.
29. Su MJ, Bikle DD, Mancianti ML, Pillai S. 1, 25-dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. J Biol Chem 269;14723-14729.
30. De Haes P, Garmyn M, Degreef H, Vantieghem K, Bouillon R, Segaert S. 1, 25-dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. J Cell Biochem 89:663-673.
31. Lappe JM, Traver-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591.
32. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
33. Adams LA, Lymp JF, St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005;129:113-121.
34. Liangpunsakul S, Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci 2011;56:2124-2129.
35. Barchetta I, Angelico F, Del Ben M, et al. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011;9:85.
36. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007;17:517-524.
37. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-1523.
38. Cusi K. Role of insulin resistance in lipotoxicity in nonalcoholic steatohepatitis. Clin Liver Dis 2009;13:544-563.
39. Kanuri G, Spruss A, Wangerberger S, Bischoff SC, Bergheim I. Role of tumor necrosis factor alpha in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011;22:527-534.
40. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-919.
41. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-1846.
42. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 2010;32:769-775.
43. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009;30:234-239.
44. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
45. Kim JY, van de Wall, Lapalnte M, Azzara A, Trujillo ME, Hofman SM, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117:2621-2637.
46. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-945.
47. Vaidya A, Williams JS, Forman JP. The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in large cohorts: the NHS and the HPFS. Obesity 2012;20:186-191.
48. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby E. Vitamin D in relationship to metabolic risk factors, insulin sensitivity, and adiponectin in a young Middle-Eastern population. Eur J Endocrinol 2009;160:965-971.
49. Nimitphong H, Changprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B. The association between vitamin D status and circulating adiponectin independent of adiposity in subjects with abnormal glucose tolerance. Endocrine 2009;36:205-210.
50. Kakuma T, Lee Y, Higa M, Wang Z, Pan W, Shimomura I, Unger RH. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A 2000;97:8536-8541.
51. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis in therapy. Mediators Inflamm 2009;2009:1-8.
52. Zhang J, Lei T, Chen X, Long H, Zhou L, Huang J, et al. Resistin upregulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathways. Inflammation 2010;33:25-33.
53. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:97-91.
54. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin-6 and tumor necrosis factor-alpha expression. Gut 2010;59:1259-1264.
55. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, et al. Suppressor of cytokine signaling (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746.
56. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AM, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350.
57. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012;55:1103-1111.
58. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-1772.
59. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008;87:1219-1223.
60. Shi H, Kikoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced resistance. J Clin Invest 2006;116:3015-3025.
61. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, et al. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007;56:1986-1998.
62. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010;328:228-231.
63. Miura K, Seki E, Ohnishi H, Brenner DA. Role of Toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010;366:28-47.
64. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Clin Endocrinol 2013;368:17-19.
65. Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, Pang KS. 1alpha, 25-dihydroxyvtaimin D(3) triggered vitamin D receptor and FXR receptor-like effects in rat intestine and liver in vivo. Biopharm Drug Dispos 2009;30:457-75.
66. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-858.
67. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetaminde-induced liver fibrosis in rats. Gut 2011;60:1728-1737.
68. Seydel S, Beilfuss A, Kahraman A, Aksoy K, Gerken G, Akkiz H, et al. Vitamin D ameliorates stress ligand expression elicited by free fatty acids in the hepatic stellate line LX-2. Turk J Gastroenterol 2011;22:400-407.
69. Nakano T, Chen YF, Lai CY, Hsu LW, Chang YC, Deng JY, et al. Impact of artificial sunlight on the progress of NAFLD in rats. J Hepatol 2011;55:415-425.
70. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle_Bladou C, Renou C, et al. A randomized controlled trial of high-dose UDCA for NASH. J Hepatol 2011;54:1011-1019.
71. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, et al. A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89:252-257.
72. Van der Poorten, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liv Dis 2008;12:805-824.
73. Rosen C. Vitamin D insufficiency. N Engl J Med 2011;364:248-254.
74. Osborn J, Germann A, St Anna L. Clinical inquiries. Which regimen treated vitamin D deficiency most effectively? J Fam Pract 2011;60:681-683.